SGLT2 Inhibitors in managing Type 2 diabetes, using evidence-based insights and real-world clinical applications
Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Companys ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Companys public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR

The Human Clinical Trial: What Happened in Real Patients The researchers conducted a 12-week proof-of-concept clinical trial in patients with obesity and type 2 diabetes treated with semaglutide, escalated from 0.25 mg to 1 mg weekly
Comparing Wegovy Options for Weight Loss After huge anticipation, Wegovys oral tablet launched in the U.S
These innovative weight loss medications have transformed the lives of millions of Americans